Vincov-19 COVID Drug

March 12, 2022

With the completion of clinical trials that demonstrated excellent results, the first indigenous drug to treat COVID-19 named Vincov-19 is expected to be made available to the public soon.

Overview:

CSIR-Centre for Cellular & Molecular Biology (CCMB), VINS Bioproducts, and the University of Hyderabad (UoH) has collaborated to create the drug ‘Vincov-19.’

How is this drug created?

To create this drug, the SARS-CoV-2 virus is inactivated and injected into horses. Then the anti-bodies that are generated through the blood serum are synthesized and then purified and turned into a drug. This drug is then injected into humans to neutralise the COVID virus.

About CSIR-Centre for Cellular & Molecular Biology

The CCMB is an Indian fundamental life science research institute based in Hyderabad. UNESCO’s Global Molecular and Cell Biology Network have designated CCMB as a “Centre of Excellence.” It is a leading research institute that conducts high-quality basic research and training in areas of modern biology, as well as promoting centralised national facilities for new techniques in interdisciplinary fields of biology. On April 1, 1977, it was established as a semi-autonomous centre.

Conclusion

The pandemic has demonstrated that the country must become self-sufficient in terms of healthcare, rather than relying only on imports. CCMB and other scientific institutes rose to the challenge in a short period of time, developing diagnostic kits, testing facilities, gadgets, genomics, and working on over 170 possible regents and drugs.

« Previous Post Next Post »